Trexo Robotics (OBIO Pre-CAAP 2018 Company) was featured as one of The 10 Most Innovative Medical Devices Companies in 2018 by Insights Care, a publication that covers important issues and trends shaping the future of the healthcare industry. 

Charles Plant at the Impact Centre, in partnership with Openview and Communitech, examined thousands of software companies to uncover their secrets to driving growth. The published report sets out important growth metrics, particularly relevant for companies selling Software as a Service (SaaS).

Employee health provider HumanaCare announced that it has provided access to therapy for 1.3 million Canadians since acquiring TranQool (OBIO Pre-CAAP 2016 Company) in May 2018.

As part of the 2018 MedTech Conference, the MedTech Canada Innovation Breakfast Seminar will cover the topic of “Connected Medical Devices - New Paradigms of Care” and will feature US and Canadian experts.

McMaster’s new Fraunhofer Project Centre for Biomedical Engineering and Advanced Manufacturing (FPC-BEAM) will be hosting a workshop titled “Developing Clinical Point-of-Care (POC) Diagnostics for Improving Healthcare Outcomes” at the McMaster Innovation Park on September 26th and 27th.

Jessica Ching (Eve Kit, OBIO CAAP 2013 Company) and Noureddin Chahrour (AdrenalEase, OBIO Pre-CAAP 2018 Company) have been nominated in the Toronto Region category for the 2018 Manning Innovation Awards. The winners will be announced later this fall, and will be celebrated at the 2018 Manning Innovation Awards Dinner on October 24, 2018.

Elucid Labs was named a finalist for the 2018 ElevatR Pitch Competition run by Elevate TechFest, and will compete for over $1M in potential funding.

Antibe Therapeutics announced that it has entered into an exclusive licensing agreement with Kwang Dong Pharmaceutical for the development and commercialization of Antibe’s lead drug, ATB-346, in South Korea.

Interesting monthly science review from Bloom Burton & Co highlights scientific achievements from across the country.

Iris Technologies' Non-LCD Computer Screen was used in a concussion study published in the Journal of Neurotrauma.

iGan Partners is seeking innovative Canadian healthcare technology companies to pitch for a $250,000 seed investment. They are looking for dynamic entrepreneurs who are building innovative medical devices, diagnostics or services in the areas of cancer, diabetes and mental health

Join 3,000 of the world's leading medtech executives September 24-26, 2018 in Philadelphia, PA. The MedTech Conference features world-class plenary speakers, a wide array of educational programming, valuable networking and business development opportunities.

Spxtrm AI's automated, machine learning system is being used and further developed in West Park Healthcare Centre's Acquired Brain Injury Behavioural Services rehabilitation center to help treat and manage aggressive patients.

7D Surgical Inc announced that it has entered into a new supply agreement for the distribution of its innovative image guidance technologies with LifeHealthcare Group, a leading independent provider of medical devices and healthcare solutions in Australia and New Zealand.

On September 27, 2018 the UK's Department for International Trade (DIT) will be hosting a networking and info session for Canadian Health Science companies interested in opportunities in the UK.

Hosted by Demy-Colton and the EBD Group, the Biotech showcase is an investor partnering conference for health science companies and service providers. The conference runs January 7th-9th, 2019 at the Hilton San Francisco Union Square.

ImmunoBiochem has received an investment from, and entered a new co-development partnership with the Centre for Commercialization of Antibodies and Biologics (CCAB). The goal of the agreement is to develop ImmunoBiochem’s lead candidate towards regulatory filings.

A new round of funding for AI research is now available for Canadian SMEs who are, or will, partner with York University.

Application Deadline: September 27, 2018 at 4 PM

Click here to learn more

A team from Adapsyn Bioscience and McMaster University will receive C$6 million as part of a larger C$21 million investment to Genome Canada's Genomic Applications Partnership Program (GAPP).